|
20 Aug 2019 |
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis
|
|
20 Aug 2019 |
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
|
|
20 Aug 2019 |
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
|
|
20 Aug 2019 |
Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-6219
|
|
19 Aug 2019 |
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
|
|
19 Aug 2019 |
On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer
|
|
19 Aug 2019 |
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
|
|
19 Aug 2019 |
Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
|
|
17 Aug 2019 |
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
|
|
17 Aug 2019 |
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
|
|
16 Aug 2019 |
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
|
|
16 Aug 2019 |
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
|
|
15 Aug 2019 |
Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy
|
|
15 Aug 2019 |
FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
|
|
14 Aug 2019 |
LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
|
|
14 Aug 2019 |
Emalex Biosciences Announces First Patient Enrolled in Phase 2b Clinical Study to Evaluate the Efficacy and Safety of Ecopipam Tablets for the Treatment of Pediatric Patients with Tourette Syndrome
|
|
14 Aug 2019 |
CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
|
|
13 Aug 2019 |
Terns Pharmaceuticals Announces Positive Interim Results From Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
|
|
13 Aug 2019 |
Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
|
|
13 Aug 2019 |
Janssen Announces European Commission Approval of Imbruvica® (ibrutinib) for Expanded Use in Two Indications
|
|
13 Aug 2019 |
Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors
|
|
13 Aug 2019 |
Basilea starts phase 1/2 study with derazantinib in urothelial cancer
|
|
12 Aug 2019 |
First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)
|
|
12 Aug 2019 |
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis
|
|
12 Aug 2019 |
Janssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
|
